What is the role of the metabolic activity of the gut microbiota in inflammatory bowel disease? Probing for answers with stable isotopes

被引:13
作者
Barclay, Andrew R. [1 ]
Morrison, Douglas J. [2 ]
Weaver, Lawrence T. [1 ]
机构
[1] Univ Glasgow, Div Dev Med, Dept Child Hlth, Glasgow G12 8QQ, Lanark, Scotland
[2] Scottish Univ Environm Res Ctr, Stable Isotope Biochem Lab, E Kilbride, Lanark, Scotland
关键词
inflammatory bowel disease; Stable isotope probing; 16S rRNA; gut microbiota pathogenesis;
D O I
10.1097/MPG.0b013e3181615b3a
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The pathogenesis of inflammatory bowel disease remains obscure. However, there has been increasing interest in the role of the gut microbiota, focusing in particular on the "unculturable majority" of luminal and mucosal bacteria, which until recently have been difficult to study owing to the technical challenges of identification and elucidating function. Bacterial components and metabolites have been implicated in signalling to host immune systems and regulating inflammatory responses. Although the rapid expansion in techniques of molecular microbiology has increased our understanding of bacterial diversity, the tools to assess bacterial metabolic activity, and to link the 2, lag behind. Stable isotope probing is a powerful technique to link the metabolic activity and diversity of "unculturable" bacteria through isotopic labelling of biomarkers such as DNA and RNA. Progression of current stable isotope probing methodology with high-resolution oligonucleotide 16s rRNA probe technology and high precision liquid chromatographic isotope ratio mass spectrometry may facilitate application in human microbial ecology. Progress towards stable isotope probing use in vivo, in concert with other advances in bacterial metabolome analysis, will lead to the development of a dynamic picture of the metabolic activity and diversity of intestinal bacteria in inflammatory bowel disease. Such insights will, over time, lead to fuller understanding of inflammatory bowel disease pathogenesis and the development of targeted therapies to reverse the "dysbiosis" that precedes disease relapse.
引用
收藏
页码:486 / 495
页数:10
相关论文
共 100 条
[71]   Environmental genomics, the big picture? [J].
Rodríguez-Valera, F .
FEMS MICROBIOLOGY LETTERS, 2004, 231 (02) :153-158
[72]   INTERACTIONS OF THE GUT MICROFLORA AND THE HOST IN TOXICOLOGY [J].
ROWLAND, IR .
TOXICOLOGIC PATHOLOGY, 1988, 16 (02) :147-153
[73]   EFFECT OF FECAL STREAM DIVERSION ON RECURRENCE OF CROHNS-DISEASE IN THE NEOTERMINAL ILEUM [J].
RUTGEERTS, P ;
GOBOES, K ;
PEETERS, M ;
HIELE, M ;
PENNINCKX, F ;
AERTS, R ;
KERREMANS, R ;
VANTRAPPEN, G .
LANCET, 1991, 338 (8770) :771-774
[74]   Short chain fatty acid regulation of signaling genes expressed by the intestinal epithelium [J].
Sanderson, IR .
JOURNAL OF NUTRITION, 2004, 134 (09) :2450S-2454S
[75]  
Sartor R Balfour, 2005, J Pediatr Gastroenterol Nutr, V40 Suppl 1, pS30, DOI 10.1097/00005176-200504001-00018
[76]   The influence of normal microbial flora on the development of chronic mucosal inflammation [J].
Sartor, RB .
RESEARCH IN IMMUNOLOGY, 1997, 148 (8-9) :567-576
[77]   Prospective survey of childhood inflammatory bowel disease in the British Isles [J].
Sawczenko, A ;
Sandhu, BK ;
Logan, RFA ;
Jenkins, H ;
Taylor, CJ ;
Mian, S ;
Lynn, R .
LANCET, 2001, 357 (9262) :1093-1094
[78]   EFFECT OF BUTYRATE ENEMAS ON THE COLONIC MUCOSA IN DISTAL ULCERATIVE-COLITIS [J].
SCHEPPACH, W ;
SOMMER, H ;
KIRCHNER, T ;
PAGANELLI, GM ;
BARTRAM, P ;
CHRISTL, S ;
RICHTER, F ;
DUSEL, G ;
KASPER, H .
GASTROENTEROLOGY, 1992, 103 (01) :51-56
[79]   The butyrate story: old wine in new bottles? [J].
Scheppach, W ;
Weiler, F .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2004, 7 (05) :563-567
[80]   The complicated path to true causes of disease:: role of nuclear factor κB in inflammatory bowel disease [J].
Schreiber, S .
GUT, 2005, 54 (04) :444-445